In this phase III randomized study, evaluating the efficacy of adjuvant gemcitabine in resected pancreatic cancer compared to an observational group, TP53 mutations represented a negative prognostic factor for DFS in untreated patients (HR: 2.434, p = 0.005). This evidence concerns the gene TP53 and familial pancreatic carcinoma.